Management of Rasburicase-Induced Hemolytic Anemia

This journal article explores the use of rasburicase to prevent and treat hyperuricemia in patients with tumor lysis syndrome. It advises to avoid rasburicase in patients with G6PD deficiency as they have an increased risk for hemolytic anemia and provides guidance on discontinuing use and employing supportive measures.

Journal of Hematology Oncology Pharmacy